Search

Search Constraints

You searched for: Author/Creator Tu, Shi-Ming

Search Results

1. 283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs). (9th November 2020)

2. 376 A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors. (9th November 2020)

3. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. (March 2020)

4. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. (November 2021)

7. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. Issue 10 (October 2019)

8. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. (May 2020)